Compare CAVA Group Inc (CAVA) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CAVA Group Inc vs Incyte Corporation — how do they compare? CAVA Group Inc trades at $71.34 (market cap $7.08B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 3.5× CAVA Group Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, CAVA Group Inc nearer its low. Which is the better fit depends on your goals.
| CAVA | INCY | |
|---|---|---|
Market Cap | $7.08B | $24.54B |
Sector | Consumer Cyclical | Health |
52-Week High | $97.39 | $129.93 |
52-Week Low | $43.59 | $81.61 |
Enterprise Value | $7.23B | $20.04B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CAVA Group Inc
CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.
Read more on CAVA →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
